Publication:
Alpha-mangostin attenuation of hyperglycemia-induced ocular hypoperfusion and blood retinal barrier leakage in the early stage of type 2 diabetes rats

dc.contributor.authorJariyapongskul A.
dc.contributor.authorAreebambud C.
dc.contributor.authorSuksamrarn S.
dc.contributor.authorMekseepralard C.
dc.date.accessioned2021-04-05T03:26:22Z
dc.date.available2021-04-05T03:26:22Z
dc.date.issued2015
dc.date.issuedBE2558
dc.description.abstractThe present study examined effects of alpha-mangostin (α-MG) supplementation on the retinal microvasculature, including ocular blood flow (OBF) and blood-retinal barrier (BRB) permeability in a type 2 diabetic animal model. Male Sprague-Dawley rats were divided into four groups: normal control and diabetes with or without α-MG supplementation. Alpha-mangostin (200 mg/Kg/day) was administered by gavage feeding for 8 weeks. The effects of α-MG on biochemical and physiological parameters including mean arterial pressure (MAP), OBF, and BRB leakage were investigated. Additionally, levels of retinal malondialdehyde (MDA), advance glycation end products (AGEs), receptor of advance glycation end products (RAGE), tumour necrosis factor alpha (TNF-α), and vascular endothelial growth factor (VEGF) were evaluated. The elevated blood glucose, HbA1c, cholesterol, triglyceride, serum insulin, and HOMA-IR were observed in DM2 rats. Moreover, DM2 rats had significantly decreased OBF but statistically increased MAP and leakage of the BRB. The α-MG-treated DM2 rats showed significantly lower levels of retinal MDA, AGEs, RAGE, TNF-α, and VEGF than the untreated group. Interestingly, α-MG supplementation significantly increased OBF while it decreased MAP and leakage of BRB. In conclusion, α-MG supplementation could restore OBF and improve the BRB integrity, indicating its properties closely associated with antihyperglycemic, antioxidant, anti-inflammatory, and antiglycation activities. © 2015 Amporn Jariyapongskul et al.
dc.format.mimetypeapplication/pdf
dc.identifier.citationBioMed Research International. Vol 2015, (2015)
dc.identifier.doi10.1155/2015/785826
dc.identifier.issn23146133
dc.identifier.other2-s2.0-84928561973
dc.identifier.urihttps://hdl.handle.net/20.500.14740/6245
dc.rights.holderScopus
dc.subject.otherAdvanced glycation end product
dc.subject.otherAdvanced glycation end product receptor
dc.subject.otherAlpha mangostin
dc.subject.otherAntidiabetic agent
dc.subject.otherAntiinflammatory agent
dc.subject.otherAntioxidant
dc.subject.otherCholesterol
dc.subject.otherGlucose
dc.subject.otherHemoglobin A1c
dc.subject.otherInsulin
dc.subject.otherMalonaldehyde
dc.subject.otherMangosteen extract
dc.subject.otherPlant extract
dc.subject.otherTriacylglycerol
dc.subject.otherTumor necrosis factor alpha
dc.subject.otherUnclassified drug
dc.subject.otherVasculotropin
dc.subject.otherGlucose blood level
dc.subject.otherGlycosylated hemoglobin
dc.subject.otherMangostin
dc.subject.otherTumor necrosis factor
dc.subject.otherVasculotropin A
dc.subject.otherXanthone derivative
dc.subject.otherAnimal experiment
dc.subject.otherAnimal model
dc.subject.otherAntidiabetic activity
dc.subject.otherAntiglycation activity
dc.subject.otherAntiinflammatory activity
dc.subject.otherAntioxidant activity
dc.subject.otherArticle
dc.subject.otherBlood retina barrier
dc.subject.otherCholesterol blood level
dc.subject.otherControlled study
dc.subject.otherDiabetic retinopathy
dc.subject.otherDrug activity
dc.subject.otherDrug effect
dc.subject.otherDrug efficacy
dc.subject.otherEye blood flow
dc.subject.otherGlucose blood level
dc.subject.otherHemoglobin blood level
dc.subject.otherHomeostasis model assessment of insulin resistance
dc.subject.otherHyperglycemia
dc.subject.otherInsulin blood level
dc.subject.otherMale
dc.subject.otherMean arterial pressure
dc.subject.otherMetabolic parameters
dc.subject.otherNon insulin dependent diabetes mellitus
dc.subject.otherNonhuman
dc.subject.otherPerfusion
dc.subject.otherRat
dc.subject.otherRetina blood vessel
dc.subject.otherStatistical analysis
dc.subject.otherTriacylglycerol blood level
dc.subject.otherAnimal
dc.subject.otherBlood
dc.subject.otherBlood retina barrier
dc.subject.otherComplication
dc.subject.otherDiet therapy
dc.subject.otherDrug effects
dc.subject.otherExperimental diabetes mellitus
dc.subject.otherHuman
dc.subject.otherHyperglycemia
dc.subject.otherMetabolism
dc.subject.otherNon insulin dependent diabetes mellitus
dc.subject.otherPathology
dc.subject.otherPathophysiology
dc.subject.otherAnimalia
dc.subject.otherRattus
dc.subject.otherAnimals
dc.subject.otherBlood Glucose
dc.subject.otherBlood-Retinal Barrier
dc.subject.otherDiabetes Mellitus, Experimental
dc.subject.otherDiabetes Mellitus, Type 2
dc.subject.otherDiabetic Retinopathy
dc.subject.otherHemoglobin A, Glycosylated
dc.subject.otherHumans
dc.subject.otherHyperglycemia
dc.subject.otherMale
dc.subject.otherRats
dc.subject.otherTumor Necrosis Factor-alpha
dc.subject.otherVascular Endothelial Growth Factor A
dc.subject.otherXanthones
dc.titleAlpha-mangostin attenuation of hyperglycemia-induced ocular hypoperfusion and blood retinal barrier leakage in the early stage of type 2 diabetes rats
dc.typeArticle
dspace.entity.typePublication
swu.datasource.scopushttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84928561973&doi=10.1155%2f2015%2f785826&partnerID=40&md5=45a078d21e09e60eacef53941977067a

Files